And therefore, we’re going to continue to invest to be able to support a therapeutic and ensure that we maximize the potential for PNT2002 as well as PYLARIFY recognizing they’re awesome comparable call points, specifically for urology as well as potentially medical oncology. But we’re going to ensure that we invest adequately to support the launch of PNT2002 and the significant market potential that it brings.
Operator: [Operator Instructions] Your next question comes from the line of Andy Hsieh from William Blair. Andy, your line is open. Please ask your question.
Andy Hsieh: Okay, great. Thanks for taking my question and congratulations on continued execution. I want to ask about data coming out of ESMO and the regulatory dynamics. It seems like Novartis has to wait until 2024 to make a submission decision due to the apparent detriment on overall survival with a hazard ratio of 1.16. And when you look at the internal pipeline, does that open the door for PNT2002 to potentially leapfrog Novartis as the first filer in the pre-chemo setting?
Mary Anne Heino: So it’s impossible at this point to estimate what the regulatory filing time lines will be for both products. As we’ve noted, I think, very repeatedly, we are eagerly awaiting the SPLASH data readout in fourth quarter 2023, and that will really form all of our strategy. What I will say is I think that there is a willing and open attitude of the FDA to bring these modalities to market. And I think that is something that both we and Novartis are also focused on making these treatments available and accessible to patients. And we’re very confident, and as I said, again, we’re looking forward to seeing the SPLASH data. Once we have it, we’ll be able to compare it more fully to the PSMAfore data and to have that inform our regulatory strategy and what we would see as the regulatory time line for both these products.
Operator: [Operator Instructions] And for your next question, it comes from the line of Justin Walsh from JonesTrading. Justin, your line is open. Please ask your question.
Justin Walsh: Hi. Thanks for taking the question. It might be a little early to get a solid answer on this, but I’m wondering if you can help contextualize how you view the size of the potential mid- to long-term market for an asset like MK-6240.
Mary Anne Heino: That is really a great question and one that is top of mind for us. We look at what’s happening in Alzheimer’s disease and the progress of the therapeutic candidates there. And then also the scientific communities, I would say, analysis and consideration of amyloid versus Tau imaging and what it infers about patients and where they are in their staging and where they are in their kind of their clinical timeline. And for many reasons of what are really emerging data, we see great potential for Tau imaging agents in their role in helping to not only diagnose but more importantly, stage Alzheimer’s patients. And while I’m not willing to give a dollar figure around that market now, I will say that we are very, very impressed with what the size of that market can be.
And again, we are not the only company with the Tau imaging agent under development or approved. But we think that MK-6240 offers some advantages in performance that will be important to the market. Just as a note, on an annual basis, there were 6.5 million patients who are diagnosed, and it is wonderfully still a very highly prevalent population as well. So it’s a very large market, and we are really thrilled about having the opportunity to serve it.
Operator: [Operator Instructions] And for your next question, it comes from the line of Larry Solow from CJS Securities. Larry, your line is open. Please ask your question.
